

CHADS₂ SCORE: 4

NO THERAPY: Patient's ANNUAL risk of ischemic stroke with no antithrombotic therapy: 8.5% Annual risk of major bleed: 0.6%
ASPIRIN: Patient's ANNUAL risk of ischemic stroke with aspirin: 6.6% Relative risk reduction: 22% Absolute risk reduction: 1.9% Chance of benefit per year: 1 in 53 Annual risk of major bleed: 1.1% Chance of being harmed by aspirin (per year, major bleeding): 1 in 222
WARFARIN: Patient's ANNUAL risk of ischemic stroke with warfarin INR 2-3: 2.8% Relative risk reduction: 66% Absolute risk reduction: 5.7% Chance of benefit per year: 1 in 18 Annual risk of major bleed: 2.4-2.8% Chance of being harmed by warfarin (per year, major bleeding): 1 in 56
ASPIRIN + CLOPIDOGREL : Patient's ANNUAL risk of ischemic stroke with aspirin 75-100 mg/d + clopidogrel 75 mg/d: 4.8% Relative risk reduction: 44% Absolute risk reduction: 3.7% Chance of benefit per year: 1 in 27 Annual risk of major bleed: 2.0-2.2% Chance of being harmed by aspirin+clopidogrel (per year, major bleeding): same as warfarin

Page 6

CHADS₂ SCORE: 5

NO THERAPY: Patient's ANNUAL risk of ischemic stroke with no antithrombotic therapy: 12.5% Annual risk of major bleed: 0.6%
ASPIRIN: Patient's ANNUAL risk of ischemic stroke with aspirin: 9.8% Relative risk reduction: 22% Absolute risk reduction: 2.8% Chance of benefit per year: 1 in 36 Annual risk of major bleed: 1.1% Chance of being harmed by aspirin (per year, major bleeding): 1 in 222
WARFARIN: Patient's ANNUAL risk of ischemic stroke with warfarin INR 2-3: 4.1% Relative risk reduction: 66% Absolute risk reduction: 8.4% Chance of benefit per year: 1 in 12 Annual risk of major bleed: 2.4-2.8% Chance of being harmed by warfarin (per year, major bleeding): 1 in 56
ASPIRIN + CLOPIDOGREL : Patient's ANNUAL risk of ischemic stroke with aspirin 75-100 mg/d + clopidogrel 75 mg/d: 7.0% Relative risk reduction: 44% Absolute risk reduction: 5.5% Chance of benefit per year: 1 in 18 Annual risk of major bleed: 2.0-2.2% Chance of being harmed by aspirin+clopidogrel (per year, major bleeding): same as warfarin

Page 7

CHADS₂ SCORE: 6

NO THERAPY: Patient's ANNUAL risk of ischemic stroke with no antithrombotic therapy: 18.2% Annual risk of major bleed: 0.6%
ASPIRIN: Patient's ANNUAL risk of ischemic stroke with aspirin: 14.2% Relative risk reduction: 22% Absolute risk reduction: 4.0% Chance of benefit per year: 1 in 25 Annual risk of major bleed: 1.1% Chance of being harmed by aspirin (per year, major bleeding): 1 in 222
WARFARIN: Patient's ANNUAL risk of ischemic stroke with warfarin INR 2-3: 6.0% Relative risk reduction: 66% Absolute risk reduction: 12.2% Chance of benefit per year: 1 in 8 Annual risk of major bleed: 2.4-2.8% Chance of being harmed by warfarin (per year, major bleeding): 1 in 56
ASPIRIN + CLOPIDOGREL : Patient's ANNUAL risk of ischemic stroke with aspirin 75-100 mg/d + clopidogrel 75 mg/d: 10.2% Relative risk reduction: 44% Absolute risk reduction: 8.0% Chance of benefit per year: 1 in 12 Annual risk of major bleed: 2.0-2.2% Chance of being harmed by aspirin+clopidogrel (per year, major bleeding): same as warfarin

Page 8

Literature Sources for Pocket SPARC

CHADS₂ Scoring System

Gage BF, et al. JAMA 2001;285:2864-70.

Efficacy of aspirin and warfarin

Aguilar MI, et al. Cochrane Rev 2005; CD001927.

Hart RG, et al. Ann Intern Med. 2007;146:857-867.

Aguilar MI, et al. Cochrane Database Syst Rev 2005; CD001925.

Bleeding risk with no therapy and with aspirin

Derry S et al. BMJ 2000;321:1183-7.

Bleeding risk with warfarin

Copland M, et al. Arch Intern Med 2001;161:2125-8.

ACTIVE W, Lancet 2006; 367: 1903-12.

ACTIVE-A, NEJM 2009;360 (epub 3APR09).

Clinical Practice Evaluation of SPARC calculator Sprage D, et al. AM J Health-Syst Pharm 2003; 60:427-9.

Visit www.peterloewen.com for updates.

May 2009

Page 9

CHADS₂ SCORE: 4

NO THERAPY: Patient's ANNUAL risk of ischemic stroke with no antithrombotic therapy: 8.5% Annual risk of major bleed: 0.6%
ASPIRIN: Patient's ANNUAL risk of ischemic stroke with aspirin: 6.6% Relative risk reduction: 22% Absolute risk reduction: 1.9% Chance of benefit per year: 1 in 53 Annual risk of major bleed: 1.1% Chance of being harmed by aspirin (per year, major bleeding): 1 in 222
WARFARIN: Patient's ANNUAL risk of ischemic stroke with warfarin INR 2-3: 2.8% Relative risk reduction: 66% Absolute risk reduction: 5.7% Chance of benefit per year: 1 in 18 Annual risk of major bleed: 2.4-2.8% Chance of being harmed by warfarin (per year, major bleeding): 1 in 56
ASPIRIN + CLOPIDOGREL : Patient's ANNUAL risk of ischemic stroke with aspirin 75-100 mg/d + clopidogrel 75 mg/d: 4.8% Relative risk reduction: 44% Absolute risk reduction: 3.7% Chance of benefit per year: 1 in 27 Annual risk of major bleed: 2.0-2.2% Chance of being harmed by aspirin+clopidogrel (per year, major bleeding): same as warfarin

Page 6

CHADS₂ SCORE: 5

NO THERAPY: Patient's ANNUAL risk of ischemic stroke with no antithrombotic therapy: 12.5% Annual risk of major bleed: 0.6%
ASPIRIN: Patient's ANNUAL risk of ischemic stroke with aspirin: 9.8% Relative risk reduction: 22% Absolute risk reduction: 2.8% Chance of benefit per year: 1 in 36 Annual risk of major bleed: 1.1% Chance of being harmed by aspirin (per year, major bleeding): 1 in 222
WARFARIN: Patient's ANNUAL risk of ischemic stroke with warfarin INR 2-3: 4.1% Relative risk reduction: 66% Absolute risk reduction: 8.4% Chance of benefit per year: 1 in 12 Annual risk of major bleed: 2.4-2.8% Chance of being harmed by warfarin (per year, major bleeding): 1 in 56
ASPIRIN + CLOPIDOGREL : Patient's ANNUAL risk of ischemic stroke with aspirin 75-100 mg/d + clopidogrel 75 mg/d: 7.0% Relative risk reduction: 44% Absolute risk reduction: 5.5% Chance of benefit per year: 1 in 18 Annual risk of major bleed: 2.0-2.2% Chance of being harmed by aspirin+clopidogrel (per year, major bleeding): same as warfarin

Page 7

CHADS₂ SCORE: 6

NO THERAPY: Patient's ANNUAL risk of ischemic stroke with no antithrombotic therapy: 18.2% Annual risk of major bleed: 0.6%
ASPIRIN: Patient's ANNUAL risk of ischemic stroke with aspirin: 14.2% Relative risk reduction: 22% Absolute risk reduction: 4.0% Chance of benefit per year: 1 in 25 Annual risk of major bleed: 1.1% Chance of being harmed by aspirin (per year, major bleeding): 1 in 222
WARFARIN: Patient's ANNUAL risk of ischemic stroke with warfarin INR 2-3: 6.0% Relative risk reduction: 66% Absolute risk reduction: 12.2% Chance of benefit per year: 1 in 8 Annual risk of major bleed: 2.4-2.8% Chance of being harmed by warfarin (per year, major bleeding): 1 in 56
ASPIRIN + CLOPIDOGREL : Patient's ANNUAL risk of ischemic stroke with aspirin 75-100 mg/d + clopidogrel 75 mg/d: 10.2% Relative risk reduction: 44% Absolute risk reduction: 8.0% Chance of benefit per year: 1 in 12 Annual risk of major bleed: 2.0-2.2% Chance of being harmed by aspirin+clopidogrel (per year, major bleeding): same as warfarin

Page 8

Literature Sources for Pocket SPARC

CHADS₂ Scoring System

Gage BF, et al. JAMA 2001;285:2864-70.

Efficacy of aspirin and warfarin

Aguilar MI, et al. Cochrane Rev 2005; CD001927.

Hart RG, et al. Ann Intern Med. 2007;146:857-867.

Aguilar MI, et al. Cochrane Database Syst Rev 2005; CD001925.

Bleeding risk with no therapy and with aspirin

Derry S et al. BMJ 2000;321:1183-7.

Bleeding risk with warfarin

Copland M, et al. Arch Intern Med 2001;161:2125-8.

ACTIVE W, Lancet 2006; 367: 1903-12.

ACTIVE-A, NEJM 2009;360 (epub 3APR09).

Clinical Practice Evaluation of SPARC calculator Sprage D, et al. AM J Health-Syst Pharm 2003; 60:427-9.

Visit www.peterloewen.com for updates.

May 2009

Page 9

Pocket **SPARC**

**Stroke
Prevention
Atrial Fibrillation
Risk
Calculator**

SPARC Developed by:
Peter Loewen, Pharm D,
Vancouver, BC
Excel version available at:
www.peterloewen.com



Pocket **SPARC**

**Stroke
Prevention
Atrial Fibrillation
Risk
Calculator**

SPARC Developed by:
Peter Loewen, Pharm D,
Vancouver, BC
Excel version available at:
www.peterloewen.com

